TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
1 . A method of treating a patient having short bowel syndrome with at least about 10% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state, who receives an amount of parenteral nutrition each week, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering h(Gly2)GLP-2 to said patient using a dosing regimen effective to increase the endogenous GLP-2 in the fed state of said patient.
2 . A method as defined in claim 2 , wherein the h(Gly2)GLP-2 is administered at a daily dose of from 30 to 150 μg/kg.
3 . A method as defined in claim 1 , wherein said patient has at least about 15% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
4 . A method as defined in claim 3 , wherein said patient has at least about 20% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
5 . A method as defined in claim 4 , wherein said patient has at least about 25% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
6 . A method as defined in claim 5 , wherein said patient has at least about 30% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
7 . A method as defined in claim 6 , wherein said patient has at least about 35% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
8 . A method as defined in claim 7 , wherein said patient has at least about 40% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
9 . A method as defined in claim 8 , wherein said patient has at least about 45% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
10 . A method as defined in claim 9 , wherein said patient has at least about 50% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
11 . A method as defined in claim 10 , wherein said patient has at least about 55% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
12 . A method as defined in claim 11 , wherein said patient has at least about 60% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
13 . A method as defined in claim 12 , wherein said patient has at least about 65% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
14 . A method as defined in claim 13 , wherein said patient has at least about 70% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
15 . A method as defined in claim 14 , wherein said patient has at least about 80% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
16 . A method as defined in claim 15 , wherein said patient has at least about 90% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state.
17 . A method as defined in claim 1 , wherein said patient produces at least about 10 pmol/L of endogenous GLP-2 levels in the fed state.
18 . A method as defined in claim 17 , wherein said patient produces at least about 15 pmol/L of endogenous GLP-2 levels in the fed state.
19 . A method as defined in claim 18 , wherein said patient produces at least about 20 pmol/L of endogenous GLP-2 levels in the fed state.
20 . A method as defined in claim 19 , wherein said patient produces at least about 25 pmol/L of endogenous GLP-2 levels in the fed state.
21 . A method as defined in claim 20 , wherein said patient produces at least about 30 pmol/L of endogenous GLP-2 levels in the fed state.
22 . A method as defined in claim 21 , wherein said patient produces at least about 35 pmol/L of endogenous GLP-2 levels in the fed state.
23 . A method as defined in claim 22 , wherein said patient produces at least about 40 pmol/L of endogenous GLP-2 levels in the fed state.
24 . A method as defined in claim 23 , wherein said patient produces at least about 45 pmol/L of endogenous GLP-2 levels in the fed state.
25 . A method as defined in claim 24 , wherein said patient produces at least about 50 pmol/L of endogenous GLP-2 levels in the fed state.
26 . A method as defined in claim 25 , wherein said patient produces at least about 55 pmol/L of endogenous GLP-2 levels in the fed state.
27 . A method as defined in claim 26 , wherein said patient produces at least about 60 pmol/L of endogenous GLP-2 levels in the fed state.
28 . A method as defined in claim 27 , wherein said patient produces at least about 65 pmol/L of endogenous GLP-2 levels in the fed state.
29 . A method as defined in claim 28 , wherein said patient produces at least about 70 pmol/L fed of endogenous GLP-2 levels in the fed state.